Drug Database
HF

HFA Modulite techn

✓ Approved

Chiesi Farmaceutici S.p.A. · therapeutic agent

What is HFA Modulite techn?

HFA Modulite techn is a therapeutic agent developed by Chiesi Farmaceutici S.p.A.. It is approved for therapeutic indications via inhaled.

Drug Profile

CompanyChiesi Farmaceutici S.p.A.
RouteInhaled
StatusApproved
Sources: ClinicalTrials.gov, Chiesi Farmaceutici S.p.A.

Therapeutic Indications

HFA Modulite techn is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresOral appliance application✓ Approved

Related Research Articles

PubMedJournal of clinical orthopaedics and trauma2026-06-08

Short term outcome of a two-staged approach for untreated radial longitudinal deficiency in children over two years of age.

Pandey Ritesh Arvind RA, Jhariya Rupendra R

Centralization of the hand over distal ulna remains the cornerstone of management for congenital radial longitudinal deficiency (CRLD). However, centralization alone presents several technical challenges. Gradual soft tissue distraction prior to centralization is usually helpful in tackling these issues. The currentstudy observed the short term outcomes of a two-staged procedure where wrist was gradually distracted with an external fixator before performing centralization. Retrospective analysis of 20 hands (14 patients) with Heikel type 3-4 CRLD managed by two-staged approach between year 2020 and 2024 was done. In first stage, gradual distraction of the wrist was performed with an external fixator. Once sufficient distraction was achieved, centralization of wrist over distal ulna was done as second stage without doing any tendon transfer across the wrist. Clinical hand-forearm angle (HFA) and radiological ulna-metacarpal angle (UMA) before and after treatment were compared to assess the amount of correction. Mean age of children was 33.1 months; mean follow-up after centralisation was 26 months (range 18-48 months). Radial deviation was corrected from 74.3° to 12.6° (correction 61.7°, p < 0.001) and volar flexion from 66.4° to 12.0° (correction 54.5°, p < 0.001). Radiological UMA correction was 64.0° (AP, p < 0.001) and 45.5° (lateral, p < 0.001). Complications included pin-tract infection (2 hands), physeal widening (1 hand), K-wire breakage (1 hand) and finger contractures (5 hands). All were managed conservatively without compromising the final outcome. A two-staged approach of gradual distraction and centralisation achieves satisfactory preliminary short term deformity correction in children with severe RLD presenting after two years. Prior distraction simplifies centralisation and obviates aggressive releases.

PMID 42254274
Read full article →
PubMedMultidisciplinary respiratory medicine2026-06-05

Recupera e Respira: A sustainable pilot model for disposal of inhalers.

Siscaro Gherardo G, Mecchia Stefano S, Gigante Giovanni G, Luoni Benedetta B et al.

Recupera e Respira, a pilot project launched in the Friuli Venezia Giulia region in Italy in 2022, addresses the environmental impact of improper disposal of respiratory inhalers. When these medical devices are disposed of as regular household waste without segregation, they contribute to pollution with aluminum and plastic, and emission of residual hydrofluoroalkane (HFA). In collaboration with Federfarma, the national association representing over 19,000 private pharmacies affiliated with Italy's National Health Service, and with the support of Assinde, a company specializing in pharmaceutical returns management and the safe disposal of expired or unused medicines, Chiesi Italy suggested and implemented an institutionally approved collection and disposal system for empty inhalers. This initiative achieved a recovery rate of 24.6% over 3 years (calculated from IQVIA sell-out data referring to the Friuli Venezia Giulia region for September 2022 to June 2025), collecting over 111,000 inhalers from regional pharmacies. Proper disposal occurred at certified facilities capable of neutralizing hazardous components at high temperatures. The project highlights the role of pharmacies in educating patients and facilitating sustainable healthcare practices. An increase in recovery rates from 22.6% to 27.3% was observed in the first 2 years of project, with a sightly decrease over the third year. Overall, this study demonstrates the model's potential scalability, aligning with Chiesi's net zero goals by 2035. The study highlights how innovative waste management systems can effectively reduce the environmental burden of inhalers and foster public engagement in sustainability.

PMID 42246273
Read full article →
PubMedMaterials today. Bio2026-06-03

Edaravone-based precision antioxidative therapy alleviates intervertebral disc degeneration via the Nrf2/Aldh3a1 axis.

Gong Yuhang Y, Wu Xinyu X, Fang Zhiyu Z, Tang Fang F et al.

Oxidative stress-induced dysfunction of nucleus pulposus (NP) cells is a key driver of intervertebral disc degeneration (IDD), promoting accelerated cellular senescence and extracellular matrix (ECM) degradation. Moreover, effective regulation of redox homeostasis within the avascular intervertebral disc remains challenging due to rapid drug clearance and poor targeting. To address these issues, we developed a precision antioxidative therapeutic strategy by integrating edaravone (ED), an FDA-approved free radical scavenger, into a novel reactive oxygen species (ROS)-responsive hydrogel (ED@HFA) for localized intradiscal delivery. Mechanistically, ED restored redox balance and preserved ECM homeostasis in NP cells under oxidative stress by activating the Nrf2/Aldh3a1 signaling axis. From a delivery perspective, ED@HFA employs hyaluronic acid methacrylate (HAMA) as a biomimetic matrix and incorporates 3-fluorophenylboronic acid (FPBA) to construct a redox-sensitive crosslinked network. The electron-withdrawing fluorine substituent in FPBA markedly enhances responsiveness to pathological ROS levels for on-demand drug release. In a puncture-induced rat IDD model, this delivery system effectively preserved disc structural integrity and attenuated IDD progression. Collectively, this precision antioxidative delivery platform, combining the safe and effective antioxidant ED with a novel ROS-responsive hydrogel, provides a promising therapeutic approach for the treatment of IDD.

PMID 42231915
Read full article →
PubMedESC heart failure2026-06-01

Phenotyping patients with a low-flow, low-gradient aortic stenosis and a preserved ejection fraction undergoing TAVI.

van Bergeijk K H KH, Roski F F, Venema C S CS, Rheude T T et al.

In patients undergoing transcatheter aortic valve implantation (TAVI), a low flow, low-gradient (LF-LG) is often caused by reduced left ventricular ejection fraction (LVEF). However, characteristics and causes of worse outcomes in patients with a paradoxical LF-LG with preserved ejection fraction (pEF) are less well understood. To phenotype patients with LF-LG pEF, based on unsupervised echocardiographic clustering. We included 827 patients undergoing TAVI in a tertiary medical centre in the Netherlands. LF-LG pEF was defined as LVEF≥50%, Aortic Valve Area: ≤ 1.0 cm2, mean gradient <40 mmHg, and a stroke volume index <35ml/m2. K-means clustering was performed using principal component analysis on 323 AI-assessed echocardiographic parameters (US2.ai). Validation was performed both internal (n=405) and external (n=173) (TUMunich, Germany). From 827 patients undergoing TAVI, 216 patients (35%) had a LF-LG pEF status (mean age of 78.8 (± 7.19) years, 57.9% female), in which two clusters were identified. Patients in cluster 1 (n=77) were characterized by distinct echocardiographic features related to HFpEF, including larger left (LA) and right atrial dimensions (as shown by volume, area, length, width and circumference), and impaired left ventricular global longitudinal strain and a reduced LA reservoir strain (in different echocardiographic views). Also, they were older, and had higher rates of atrial fibrillation (AF) and heart failure (HF), and higher HFpEF scores (49.4% H2FPEF score ≥6 and 71.4% HFA-pEFF score ≥5), compared to cluster 2 (n=139). Cluster 1 had a higher risk of 1-and 5-year cardiovascular mortality and HF-hospitalisations, similar to classical LF-LG patients. Internal and external validation revealed similar results. One-third of TAVI patients with LF-LG aortic stenosis have a typical HFpEF/AF-phenotype and a poor prognosis. They may benefit from guideline-directed medical therapies for patients with HFpEF, including SGLT-2 inhibitors and MRA.

PMID 42219263
Read full article →
PubMedJACC. Cardiovascular imaging2026-05-29

Machine Learning Model Using Pre-Cancer Therapy Cardiac Magnetic Resonance Images to Predict Cancer Therapy-Related Cardiac Dysfunction.

Yu Christopher C, Peikari Mohammad M, Labib Dina D, Houbois Christian P CP et al.

Predicting risk of cancer therapy-related cardiac dysfunction (CTRCD) remains challenging. The purpose of this study was to assess if deep learning (DL) approaches using cardiac magnetic resonance (CMR) images before cancer therapy can predict subsequent CTRCD and compare them with clinical and conventional imaging models. Women with HER2+ breast cancer receiving anthracyclines and trastuzumab from 3 prospective studies (Toronto, Canada: EMBRACE-MRI, SPARE-HF; and Calgary, Canada: CIROC) were included. Patients were assessed before cancer therapy, after anthracycline, and trimonthly with repeated echocardiography and CMR. CTRCD was defined according to CMR. We calculated the HFA-ICOS risk score and measured CMR and echocardiography volumetric and functional parameters. Deep convolutional neural network architectures were used with pre-cancer therapy CMR short-axis cine images to develop image-based DL models to predict CTRCD. The Toronto patients were used for model derivation and internal validation; the Calgary patients were used for external validation. A total of 229 patients (mean age 50.4 ± 9.7 years) were included: 176 in the internal (52 CTRCD events) development cohort and 53 in the external data set (14 CTRCD events). Our pre-cancer therapy CMR DL model demonstrated an AUC of 0.85 (95% CI: 0.69-0.97) and F1 score 0.69 (95% CI: 0.47-0.86) to predict CTRCD. On external validation, the DL model had an AUC of 0.80 (95% CI: 0.58-0.86) and F1 score of 0.55 (95% CI: 0.32-0.69). In comparison, the best-performing models using HFA-ICOS risk score, CMR, and echocardiographic parameters demonstrated, respectively, AUCs of 0.66 (95% CI: 0.53-0.75), 0.59 (95% CI: 0.41-0.73), 0.62 (95% CI: 0.44-0.78) and F1 scores of 0.56 (95% CI: 0.47-0.61), 0.20 (95% CI: 0.00-0.42) and 0.36 (95% CI: 0.12-0.62) to predict CTRCD. A DL model using pre-cancer therapy CMR short-axis cines can predict future CTRCD risk better than clinical or manually quantified imaging models.

PMID 42212994
Read full article →
PubMedPlants (Basel, Switzerland)2026-05-27

Structural, Evolutionary, and Regulatory Divergence of FAH12 from FAD2 Reveals Recurrent Independent Neofunctionalization Underlying Ricinoleic Acid Biosynthesis in Ricinus communis.

Meng Fanqing F, Sun Jing J, Zhou Zekun Z, Yuan Guofang G et al.

Ricinus communis is the primary commercial source of ricinoleic acid (RA), a hydroxy fatty acid (HFA) synthesized by the fatty acid hydroxylase FAH12, which evolved from the Δ12-oleate desaturase FAD2. However, the evolutionary origins and diversification mechanisms of FAH12 across HFA-producing plants remain poorly understood. Here, we performed a comprehensive cross-species analysis of FAH12 and FAD2 homologs by integrating sequence analysis, structural modeling, phylogenetic reconstruction, and transcriptomic profiling. Across all currently available HFA-producing plant lineages, we found that amino acid substitutions associated with hydroxylase activity exhibit strong lineage-specific patterns rather than universal conservation, indicating multiple evolutionary solutions to catalytic divergence. Phylogenetic and synteny analyses further suggest that FAH12 arose independently from ancestral FAD2 duplications in distinct plant lineages, supporting a model of recurrent independent neofunctionalization. Transcriptomic and qRT-PCR analyses reveal that FAH12 exhibits a highly specialized endosperm-preferential expression pattern and is embedded within a regulatory network that is partially decoupled from that of FAD2. Together, these findings demonstrate that FAH12 evolution is driven by recurrent independent origins coupled with transcriptional specialization, providing a framework linking structural variation, evolutionary history, and regulatory divergence for understanding and engineering hydroxy fatty acid biosynthesis in plants.

PMID 42197677
Read full article →

+3353 more articles available with a free account

Sign up free to view all articles →

Ask about HFA Modulite techn